The latest price target for Rubius Therapeutics Inc Com (OTC:RUBY) was reported by Guggenheim on September 13, 2022. The analyst firm set a price target for $0.00 expecting RUBY to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Rubius Therapeutics Inc Com (OTC:RUBY) was provided by Guggenheim, and Rubius Therapeutics Inc Com downgraded their neutral rating.

There is no last upgrade for Rubius Therapeutics Inc Com

The last downgrade for Rubius Therapeutics Inc Com happened on September 13, 2022 when Guggenheim changed their price target from N/A to N/A for Rubius Therapeutics Inc Com.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rubius Therapeutics Inc Com, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rubius Therapeutics Inc Com was filed on September 13, 2022 so you should expect the next rating to be made available sometime around September 13, 2023.

While ratings are subjective and will change, the latest Rubius Therapeutics Inc Com (RUBY) rating was a downgraded with a price target of $0.00 to $0.00. The current price Rubius Therapeutics Inc Com (RUBY) is trading at is $0.06, which is out of the analyst’s predicted range.